- Conditions
- Pompe Disease
- Interventions
- Cipaglucosidase alfa, Miglustat, Alglucosidase alfa or Avalglucosidase alfa, Untreated
- Biological · Drug · Other
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Irvine, California • Jacksonville, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pompe Disease
- Interventions
- ATB200, AT2221
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Orange, California • Gainesville, Florida + 9 more
- Conditions
- Pompe Disease Infantile-Onset
- Interventions
- ATB200, AT2221
- Biological · Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 0 Years to 17 Years
- U.S. locations
- 2
- States / cities
- Oakland, California • Gainesville, Florida
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- Cipaglucosidase Alfa, Miglustat
- Biological · Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 6 more
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- Cipaglucosidase Alfa, Miglustat, Alglucosidase Alfa, Placebo
- Biological · Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 21 more
- Conditions
- Glycogen Storage Disease Type II Infantile Onset
- Interventions
- Cipaglucosidase alfa, Miglustat
- Biological · Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Gainesville, Florida • Atlanta, Georgia • Durham, North Carolina + 3 more
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- AT2221, ATB200
- Drug · Biological
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Irvine, California • Gainesville, Florida + 14 more